Methionine and kynurenine activate oncogenic kinases in glioblastoma, and methionine deprivation compromises proliferation

Clinical Cancer Research

Volumn 22, Issue 14, 2016, Pages 3513-3523

  Palanichamy, Kamalakannan ^a   Thirumoorthy, Krishnan ^a,b   Kanji, Suman ^a   Gordon, Nicolaus ^a   Singh, Rajbir ^a   Jacob, John R ^a   Sebastian, Nikhil ^a   Litzenberg, Kevin T ^a   Patel, Disha ^a   Bassett, Emily ^a   Ramasubramanian, Brinda ^a   Lautenschlaeger, Tim ^a   Fischer, Steven M ^c   Ray Chaudhury, Abhik ^d   Chakravarti, Arnab ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b VIT UNIVERSITY   (India)

^c AGILENT TECHNOLOGIES   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE; 5' METHYLTHIOADENOSINE PHOSPHORYLASE; KYNURENINASE; KYNURENINE; KYNURENINE MONOOXYGENASE; METHIONINE; PHOSPHATASE; PROTEIN PP2A A; PROTEIN PP2A B; PROTEIN PP2A C; TRYPTOPHAN; TUMOR MARKER; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE; 5'-METHYLTHIOADENOSINE PHOSPHORYLASE; PURINE NUCLEOSIDE PHOSPHORYLASE;

AMINO ACID METABOLISM; ARTICLE; ASTROCYTE; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; COMPUTER MODEL; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; MTAP GENE; ONCOGENE; PRIORITY JOURNAL; TRANSGENE; TUMOR ESCAPE; TUMOR GROWTH; CELL LINE; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TUMOR CELL CULTURE;

ASTROCYTES; BIOMARKERS, TUMOR; CARCINOGENESIS; CELL LINE; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLIOBLASTOMA; HUMANS; KYNURENINE; MASS SPECTROMETRY; METABOLOMICS; METHIONINE; ONCOGENES; PURINE-NUCLEOSIDE PHOSPHORYLASE; TRYPTOPHAN; TUMOR CELLS, CULTURED;

EID: 84978427996     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2308     Document Type: Article

References (50)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study:5-yearanalysisoftheEORTC-NCICtrial.Lancet Oncol 2009;10:459-66.
2. Bowen BP, Northen TR. Dealing with the unknown: metabolomics and metabolite atlases. J Am Soc Mass Spectrom 2010;21:1471-6.
3. Mayr M. Metabolomics: ready for the prime time?Circ Cardiovasc Genet 2008;1:58-65.
4. Ryan D, Robards K. Metabolomics: The greatest omics of them all?Anal Chem 2006;78:7954-8.
5. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-4.
6. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012;336:1040-4.
7. Weckwerth W, Fiehn O. Can we discover novel pathways using metabolomic analysis?Curr Opin Biotechnol 2002;13:156-60.
8. Zhang GF, Sadhukhan S, Tochtrop GP, Brunengraber H. Metabolomics, pathway regulation, and pathway discovery. J Biol Chem 2011;286:23631-5.
9. Goldsmith P, Fenton H, Morris-Stiff G, Ahmad N, Fisher J, Prasad KR. Metabonomics: a useful tool for the future surgeon. J Surg Res 2010; 160:122-32.
10. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009;15:431-40.
11. Cuperlovic-Culf M, Barnett DA, Culf AS, Chute I. Cell culture metabolomics: applications and future directions. Drug Discov Today 2010;15:610-21.
12. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004;4:551-61.
13. Khoo SHG, Al-Rubeai M. Metabolomics as a complementary tool in cell culture. Biotechnol Appl Bioc 2007;47:71-84.
14. Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A 2005;102:5992-7.
15. Want EJ, Nordstrom A, Morita H, Siuzdak G. From exogenous to endogenous: the inevitable imprint of mass spectrometry in metabolomics. J Proteome Res 2007;6:459-68.
16. Sugimura T, Birnbaum SM, Winitz M, Greenstein JP. Quantitative nutritional studies with water-soluble, chemically defined diets. VIII. The forced feeding of diets each lacking in one essential amino acid. Arch Biochem Biophys 1959;81:448-55.
17. Poirson-Bichat F, Goncalves RA, Miccoli L, Dutrillaux B, Poupon MF. Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts. Clin Cancer Res 2000; 6:643-53.
18. Kokkinakis DM, Hoffman RM, Frenkel EP, Wick JB, Han Q, Xu M, et al. Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res 2001;61:4017-23.
19. Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011;478:197-203.
20. Broadhurst DIKD.B. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2007;2:171-96
21. Finkelstein JD.Methionine metabolism in mammals. J Nutr Biochem 1990;1:228-37.
22. Cavuoto P, Fenech MF. A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension. Cancer Treat Rev 2012;38:726-36.
23. Albers E.Metabolic characteristics and importance of the universal methionine salvage pathway recycling methionine from 50 -methylthioadenosine. IUBMB Life 2009;61:1132-42.
24. Carson DA, Nobori T, Kajander EO, Carrera CJ, Kubota M, Yamanaka H. Methylthioadenosine (MeSAdo) phosphorylase deficiency in malignancy. Adv Exp Med Biol 1988;250:179-85.
25. Lee JE, Settembre EC, Cornell KA, Riscoe MK, Sufrin JR, Ealick SE, et al. Structural comparison of MTA phosphorylase and MTA/AdoHcy nucleosidase explains substrate preferences and identifies regions exploitable for inhibitor design. Biochemistry 2004;43:5159-69.
26. Zingg JM, Jones PA. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis. Carcinogenesis 1997;18:869-82.
27. Shu S, Mahadeo DC, Liu X, Liu W, Parent CA, Korn ED. S-adenosylhomocysteine hydrolase is localized at the front of chemotaxing cells, suggesting a role for transmethylation during migration. Proc Natl Acad Sci U S A 2006;103:19788-93.
28. Palanichamy K, Acus K, Jacob JR, Chakravarti A. Clinically relevant brain tumor model and device development for experimental therapeutics. J Anal Oncol 2015;4:5-12.
29. Singhal T, Narayanan TK, Jacobs MP, Bal C, Mantil JC. 11C-methionine PET for grading and prognostication in gliomas: a comparison study with 18F-FDG PET and contrast enhancement on MRI. J Nucl Med 2012;53:1709-15.
30. Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, et al. 11Cmethionine PET for differential diagnosis of low-grade gliomas. Neurology 1998;50:1316-22.
31. Grosu AL, Weber WA, Riedel E, Jeremic B, Nieder C, Franz M, et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:64-74.
32. Matsuo M, Miwa K, Tanaka O, Shinoda J, Nishibori H, Tsuge Y, et al. Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning. Int J Radiat Oncol Biol Phys 2012;82:83-9.
33. Platten M, von Knebel Doeberitz N, Oezen I, Wick W, Ochs K. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol 2014;5:673.
34. Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 2012;72:5435-40.
35. Nobori T, Karras JG, Della Ragione F, Waltz TA, Chen PP, Carson DA. Absence of methylthioadenosine phosphorylase in human gliomas. Cancer Res 1991;51:3193-7.
36. Nobori T, Takabayashi K, Tran P, Orvis L, Batova A, Yu AL, et al. Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers. Proc Natl Acad Sci U S A 1996;93:6203-8.
37. Brat DJ, James CD, Jedlicka AE, Connolly DC, Chang E, Castellani RJ, et al. Molecular genetic alterations in radiation-induced astrocytomas. Am J Pathol 1999;154:1431-8.
38. Christopher SA, Diegelman P, Porter CW, Kruger WD. Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. Cancer Res 2002; 62:6639-44.
39. Tang B, Li YN, Kruger WD. Defects in methylthioadenosine phosphorylase are associated with but not responsible for methionine-dependent tumor cell growth. Cancer Res 2000;60:5543-7.
40. Palanichamy K, Chakravarti A. Combining drugs and radiotherapy: from the bench to the bedside. Curr Opin Neurol 2009;22:625-32.
41. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
42. Adams S, Braidy N, Bessede A, Brew BJ, Grant R, Teo C, et al. The kynurenine pathway in brain tumor pathogenesis. Cancer Res 2012;72:5649-57.
43. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 2010;185:3190-8.
44. Adams S, Teo C, McDonald KL, Zinger A, Bustamante S, Lim CK, et al. Involvement of the kynurenine pathway in human glioma pathophysiology. PLoS One 2014;9:e112945.
45. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006;176:6752-61.
46. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell 2007;130: 21-4.
47. Seshacharyulu P, Pandey P, Datta K, Batra SK. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett 2013;335:9-18.
48. Casillas AM, Amaral K, Chegini-Farahani S, Nel AE. Okadaic acid activates p42 mitogen-activated protein kinase (MAP kinase; ERK-2) in B-lymphocytes but inhibits rather than augments cellular proliferation: contrast with phorbol 12-myristate 13-acetate. Biochem J 1993; 290:545-50.
49. Puustinen P, Junttila MR, Vanhatupa S, Sablina AA, Hector ME, Teittinen K, et al. PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res 2009;69:2870-7.
50. Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, Lonser R, et al. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc Natl Acad Sci U S A 2009;106:11697-702.